6 completed, 3 terminated, 3 unknown, 1 withdrawn. 6 Phase 2, 3 Phase 3, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Withdrawn 1 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 4 | 3 | Unknown 2, Terminated 1 |
| Not applicable | 1 | Unknown 1 |
Follow elobixibat: new trials by email Literature Review of elobixibat trials Research Report on elobixibat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen 2-Liter polyethylene glycol plus elobixibat, 4-Liter polyethylene glycol - Bowel Preparation Solution, Colonoscopy | Not applicable | Unknown | Department of Medical Services Ministry of Public Health of Thailand | 360 | 2024-05-24 | 2024-12-27 |
| Elobixibat for Chronic Constipation Without Defecation Desire Elobixibat 10mg - Chronic Constipation | Phase 4 | Terminated | International University of Health and Welfare | 40 | 2023-02-09 | 2023-03-09 |
| Elobixibat for Chronic Constipation Without Defecation Desire Elobixibat 10mg - Chronic Constipation | Phase 4 | Unknown | Yokohama City University | 40 | 2022-03-01 | 2022-03-23 |
| Long-term Elobixibat for Chronic Constipation Elobixibat 10mg, Placebo - Chronic Constipation | Phase 4 | Unknown | Yokohama City University | 100 | 2021-08-06 | 2023-01-05 |
| Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g), Elobixibat 10mg + cholestyramine powder placebo, Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Yokohama City University | 102 | 2020-01-29 | 2021-11-16 |
| A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Elobixibat, Placebo oral tablet - NAFLD, NASH | Phase 2 | Completed | Albireo | 47 | 2019-06-06 | 2026-02-05 |
| Elobixibat Colonic Motor Function Study elobixibat, placebo - Chronic Idiopathic Constipation | Phase 2 | Withdrawn | Ferring Pharmaceuticals | 2015-04-01 | 2015-06-03 | |
| Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation Elobixibat 10 mg - Chronic Idiopathic Constipation | Phase 3 | Completed | Ferring Pharmaceuticals | 411 | 2013-09-01 | 2016-05-09 |
| 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation Elobixibat 10 mg, Elobixibat 5 mg, Placebo - Chronic Idiopathic Constipation | Phase 3 | Terminated | Ferring Pharmaceuticals | 376 | 2013-04-01 | 2015-10-20 |
| Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation Elobixibat 10 mg/day, Elobixibat 5 mg/day, Placebo - Chronic Idiopathic Constipation | Phase 3 | Terminated | Ferring Pharmaceuticals | 314 | 2013-04-01 | 2015-10-20 |
| Study of A3309 in Patients With Dyslipidemia A3309, Placebo - Dyslipidemia | Phase 2 | Completed | Albireo | 36 | 2010-02-01 | 2024-03-07 |
| Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation A3309, placebo - Functional Constipation | Phase 2 | Completed | Michael Camilleri, MD | 36 | 2010-01-01 | 2020-09-04 |
| Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation A3309 - Constipation, Chronic Constipation | Phase 2 | Completed | Albireo | 190 | 2009-11-01 | 2017-03-22 |
Non-alcoholic Fatty Liver Disease (2) · Constipation (1) · Dyslipidemias (1)
Ferring Pharmaceuticals (4) · Albireo (3) · Yokohama City University (3) · Department of Medical Services Ministry of Public Health of Thailand (1) · International University of Health and Welfare (1) · Michael Camilleri, MD (1)
United States (7) · Japan (4) · Canada (3) · Czechia (3) · Poland (3) · South Africa (3) · Sweden (3) · United Kingdom (3) · Belgium (2) · Brazil (2) · Germany (2) · Hungary (2) · Slovakia (2) · Israel (1) · Mexico (1)
Takaomi Kessoku, M.D., PhD. (3) · Apichet Sirinawasatien, M.D. (1) · Hans Graffner, MD (1) · Michael Camilleri, MD (1) · Takaomi Kessoku, MD.,PhD. (1)
PMID 26197999, PMID 21606974, PMID 21876564, PMID 29805116, PMID 32907904, PMID 35636802, PMID 35812817
UL1RR024150 (1)